SLCO4A1 Polyclonal antibody
SLCO4A1 Polyclonal Antibody for IP, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, IP, ELISA
Conjugate
Unconjugated
Cat no : 26399-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive IP detected in | L02 cells |
Recommended dilution
Application | Dilution |
---|---|
Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 1 publications below |
Product Information
26399-1-AP targets SLCO4A1 in WB, IP, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | SLCO4A1 fusion protein Ag23905 |
Full Name | solute carrier organic anion transporter family, member 4A1 |
Calculated Molecular Weight | 77 kDa |
Observed Molecular Weight | 77 kDa |
GenBank Accession Number | BC015727 |
Gene Symbol | SLCO4A1 |
Gene ID (NCBI) | 28231 |
RRID | AB_2880501 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
SLCO4A (Solute carrier organic anion transporter family member 4A1), also referred to as OATP4A1, is a membrane transporter protein, primarily facilitates the transmembrane transport of substances that are independent of Na+, including lipid‑soluble drugs, thyroid and adrenal hormones, and a selected few toxin (PMID: 38275113). SLCO4A1 is highly expressed in several cancers and promotes cell proliferation, migration and invasion (PMID: 28378090). Besides, SLCO4A1 was highly expressed in pancreatic cancer and could be a potential biomarker to target anticancer drugs to pancreatic carcinoma (PMID: 34924768).
Protocols
Product Specific Protocols | |
---|---|
IP protocol for SLCO4A1 antibody 26399-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cell Res Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. |